← Back to headlines
J&J's Rybrevant Faspro Granted FDA Priority Review for Head and Neck Cancer
Johnson & Johnson has received FDA priority review for its Rybrevant Faspro treatment, specifically for use in head and neck cancer, potentially accelerating its availability.
30 Jul, 13:10 — 30 Jul, 13:10
Sources
Showing 1 of 1 sources
